Moderate

Kidney transplant — maintenance immunosuppression

transplant IS · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Lifelong maintenance immunosuppression (typically a calcineurin inhibitor, antimetabolite and tapering steroid) prevents rejection while balancing infection and malignancy risk. Drug levels, graft function and complications require careful ongoing monitoring.

Red flags

  • Rising creatinine (rejection, CNI toxicity, BK nephropathy)
  • Fever/neutropenia or opportunistic infection
  • New heavy proteinuria (recurrent/de novo GN)
  • Very high or sub-therapeutic CNI levels
  • New lymphadenopathy/mass (PTLD)

Assessment

Differential diagnosis

  • Stable graft function
  • Acute rejection (if function declining)
  • Calcineurin inhibitor nephrotoxicity
  • BK virus nephropathy
  • Recurrent/de novo glomerular disease
  • Infection or dehydration causing dysfunction

Investigations

  • Tacrolimus/ciclosporin trough levels
  • Creatinine/eGFR trend and urine ACR/PCR
  • FBC (antimetabolite marrow suppression)
  • BK and CMV viral loads (surveillance)
  • Fasting glucose/HbA1c, lipids (metabolic effects)
  • Donor-specific antibodies if dysfunction/rejection suspected; biopsy if needed

Management

  • Confirm the maintenance regimen (commonly tacrolimus + mycophenolate + prednisolone) and target CNI trough by time post-transplant
  • Monitor tacrolimus troughs and titrate to target (higher early, lower long-term) while watching renal function
  • Monitor graft function (creatinine, ACR) and investigate any rise promptly (rejection, CNI toxicity, BK, obstruction, dehydration)
  • Perform protocol viral surveillance (BK, CMV) and reduce immunosuppression for BK viraemia/nephropathy
  • Give infection prophylaxis early post-transplant (co-trimoxazole for PCP, valganciclovir for CMV per risk, antifungal as indicated)
  • Screen for and manage metabolic complications: post-transplant diabetes, hypertension, dyslipidaemia
  • Counsel on skin cancer prevention and arrange dermatological/malignancy surveillance
  • Avoid drug interactions that alter CNI levels (azoles, macrolides, diltiazem, grapefruit)
  • Manage CNI nephrotoxicity by dose adjustment or conversion (e.g. to belatacept/mTOR inhibitor) where appropriate
  • Reinforce adherence — non-adherence is a major cause of late graft loss
  • Vaccinate (inactivated vaccines; avoid live vaccines) and keep screening up to date
  • Review immunosuppression, levels and complications at regular transplant clinics

Drugs & doses

Tacrolimus 0.05-0.1 mg/kg/day PO in two divided doses, titrated to trough (early target ~5-10 ng/mL, later ~4-8 ng/mL)
Mycophenolate mofetil 500-1000 mg PO twice daily (or mycophenolic acid equivalent)
Prednisolone 5-10 mg PO daily (maintenance, if not steroid-sparing)
Co-trimoxazole 480 mg PO daily (PCP prophylaxis)
Valganciclovir 900 mg PO daily, renally adjusted (CMV prophylaxis for at-risk)
Ciclosporin 3-5 mg/kg/day PO in two doses (alternative CNI), titrated to level

Disposition

Transplant nephrology clinic for lifelong follow-up. Urgent transplant centre contact for graft dysfunction, fever or suspected rejection. Biopsy for unexplained decline.

Complications & pitfalls

  • Acute and chronic rejection
  • CNI nephrotoxicity
  • Opportunistic infection (CMV, BK, PCP)
  • Post-transplant diabetes, hypertension, dyslipidaemia
  • Malignancy (skin cancers, PTLD)
  • Marrow suppression from antimetabolites

Exam pearls

  • Any unexplained creatinine rise in a transplant needs prompt work-up for rejection, CNI toxicity or BK
  • Watch for CYP3A interactions (azoles, diltiazem, macrolides) that spike tacrolimus levels
  • Reduce immunosuppression, do not add antivirals, for BK nephropathy
  • Non-adherence is a leading cause of late graft loss
  • Avoid live vaccines in immunosuppressed recipients

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.